Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Ohio State University Comprehensive Cancer Center
Fudan University
Dana-Farber Cancer Institute
Columbia University
Ruijin Hospital
UNC Lineberger Comprehensive Cancer Center
National Cancer Centre, Singapore
The Lymphoma Academic Research Organisation
The Lymphoma Academic Research Organisation
Ruijin Hospital
Sun Yat-sen University
Institute of Hematology & Blood Diseases Hospital, China
Seoul National University Hospital
Yale University
Ohio State University Comprehensive Cancer Center
The First Affiliated Hospital of Xiamen University
Institute of Hematology & Blood Diseases Hospital, China
The First Hospital of Jilin University
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Tianjin Medical University Cancer Institute and Hospital
Northwestern University
University of Michigan Rogel Cancer Center
University of Nebraska
University of Nebraska
Weill Medical College of Cornell University
Huazhong University of Science and Technology
Ruijin Hospital
The First Affiliated Hospital of Soochow University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Mayo Clinic
Ruijin Hospital
The First Affiliated Hospital with Nanjing Medical University
Czech Lymphoma Study Group
Peking University
Samsung Medical Center
University of California, San Francisco
Sun Yat-sen University
Fred Hutchinson Cancer Center
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Fondazione Italiana Linfomi - ETS
Roswell Park Cancer Institute
Zhejiang Cancer Hospital
University of Chicago
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Lymphoma Study Association
Ruijin Hospital
Sun Yat-sen University